These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8082582)

  • 21. 32P-postlabelling methods for cyclic DNA adducts.
    Watson WP; Crane AE; Steiner S
    IARC Sci Publ; 1993; (124):255-62. PubMed ID: 8225493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 32P-postlabelling analysis of DNA-adducts formed by 4-(N-carbethoxy-N-nitrosamino)-(3-pyridyl)-1-butanone and 4-oxo-4-(3-pyridyl)- butanal.
    Schmeiser HH; Castonguay A; Wiessler M
    IARC Sci Publ; 1993; (124):207-10. PubMed ID: 8225486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of DNA adduct detection between two enhancement methods of the 32P-postlabelling assay in rat lung cells.
    Whong WZ; Stewart JD; Ong T
    Mutat Res; 1992 Sep; 283(1):1-6. PubMed ID: 1380657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of formation of DNA adducts from ethylene dihalides, vinyl halides, and arylamines.
    Guengerich FP
    Drug Metab Rev; 1994; 26(1-2):47-66. PubMed ID: 8082581
    [No Abstract]   [Full Text] [Related]  

  • 25. DNA adducts of pyrrolizidine alkaloids, nitroimidazoles and aristolochic acid.
    Wiessler M
    IARC Sci Publ; 1994; (125):165-77. PubMed ID: 7806311
    [No Abstract]   [Full Text] [Related]  

  • 26. Human biomonitoring and the 32P-postlabeling assay.
    Beach AC; Gupta RC
    Carcinogenesis; 1992 Jul; 13(7):1053-74. PubMed ID: 1638670
    [No Abstract]   [Full Text] [Related]  

  • 27. Formation, detection, and role in carcinogenesis of ethenobases in DNA.
    Bartsch H; Barbin A; Marion MJ; Nair J; Guichard Y
    Drug Metab Rev; 1994; 26(1-2):349-71. PubMed ID: 8082574
    [No Abstract]   [Full Text] [Related]  

  • 28. Age- and tissue-related DNA modifications in untreated rats: detection by 32P-postlabeling assay and possible significance for spontaneous tumor induction and aging.
    Randerath K; Reddy MV; Disher RM
    Carcinogenesis; 1986 Sep; 7(9):1615-7. PubMed ID: 3742734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transplacental transfer of genotoxins and transplacental carcinogenesis.
    Autrup H
    Environ Health Perspect; 1993 Jul; 101 Suppl 2(Suppl 2):33-8. PubMed ID: 8243402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of ribonucleotides in DNA modified by oxidative damage in vitro and in vivo. Characterization by 32P-postlabeling.
    Randerath K; Reddy R; Danna TF; Watson WP; Crane AE; Randerath E
    Mutat Res; 1992 Sep; 275(3-6):355-66. PubMed ID: 1383776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overlap between mutagens and teratogens.
    Ferguson LR; Ford JH
    Mutat Res; 1997 Dec; 396(1-2):1-8. PubMed ID: 9434857
    [No Abstract]   [Full Text] [Related]  

  • 32. 32P-postlabeling assay to measure carcinogen-DNA adducts.
    Gupta RC
    Prog Exp Tumor Res; 1987; 31():21-32. PubMed ID: 3562857
    [No Abstract]   [Full Text] [Related]  

  • 33. Philip D. Lawley (1927-2011).
    Venitt S; Phillips DH
    Nature; 2012 Feb; 482(7383):36. PubMed ID: 22297963
    [No Abstract]   [Full Text] [Related]  

  • 34. Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon "Bi"-cycle.
    Schug ZT
    Biochemistry; 2018 Feb; 57(6):889-890. PubMed ID: 29368500
    [No Abstract]   [Full Text] [Related]  

  • 35. Detection of human DNA adducts by 32P-postlabeling.
    Randerath K; Randerath E
    Basic Life Sci; 1990; 53():13-32. PubMed ID: 2282030
    [No Abstract]   [Full Text] [Related]  

  • 36. Unboxing the molecular modalities of mutagens in cancer.
    Kumari S; Sharma S; Advani D; Khosla A; Kumar P; Ambasta RK
    Environ Sci Pollut Res Int; 2022 Sep; 29(41):62111-62159. PubMed ID: 34611806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical and biochemical postlabeling methods for singling out specific oxidative DNA lesions.
    Cadet J; Odin F; Mouret JF; Polverelli M; Audic A; Giacomoni P; Favier A; Richard MJ
    Mutat Res; 1992 Sep; 275(3-6):343-54. PubMed ID: 1383775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment.
    Poirier MC; Beland FA
    Chem Res Toxicol; 1992; 5(6):749-55. PubMed ID: 1489923
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of the dermal carcinogenic potential of re-refined base stocks using the modified Ames assay, PAC analysis and the 32P-postlabeling assay for DNA adduct induction.
    Dickson JR; Brinkman DW; Blackburn GR
    J Appl Toxicol; 1997; 17(2):113-7. PubMed ID: 9183054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutagenicity testing: its elusive quantiation.
    Di Carlo FJ
    Drug Metab Rev; 1979; 9(2):v-vi. PubMed ID: 487938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.